Abstract
INTRODUCTION
Trimodality treatment, which involves preoperative chemoradiotherapy followed by surgery, is the recommended approach for the majority of locally advanced oesophageal cancers [1, 2] . In the prospective randomized Chemoradiotherapy for Oesophageal Cancer Followed by Surgery Study (CROSS), the median overall survival (OS) was 49.4 months in the preoperative chemoradiotherapy plus surgery group versus 24.0 months in the surgery alone group [1] . However, a significant fraction of patients still suffer from disease recurrence after trimodality treatments [3] [4] [5] [6] [7] [8] [9] [10] . For example, 34.7% of patients in the CROSS trial experienced disease recurrence after preoperative chemoradiotherapy and surgery [3] . In a retrospective study by van Hagen et al. [4] , disease recurrence occurred in half of the patients (94 of 188) after trimodality treatments. Even in patients with pathologic complete response, which signifies no viable tumours are present in the resected specimens after preoperative chemoradiotherapy, disease recurrence, especially distant metastasis, was observed in an unacceptably high number of cases [5, 6] . In a multicentre study, Luc et al. [6] reported that disease recurrence was observed in 29.3% of patients with pathologically complete response after receiving trimodality treatment for oesophageal cancer.
Irrespective of the pathological response to preoperative chemoradiotherapy, the majority of patients experienced recurrence at distant sites [3] [4] [5] [6] [7] [8] . Whereas several factors, including poor pathological response to preoperative chemoradiotherapy, lymph nodes that are positive for disease after chemoradiotherapy, and the presence of lymphovascular invasion (LVI) and PNI, have been reported to be significantly associated with disease recurrence, the specific risk factors for distant recurrences after trimodality treatments for oesophageal cancer have been poorly defined in the literature [3, 7, 9, 10] . Understanding the patterns of disease recurrence after trimodality treatments will provides insight into the effectiveness of combined treatments, and is important for subsequent treatment planning. Given that distant metastasis predominates in patients after trimodality treatments, identifying risk factors and providing better systemic treatments to high-risk patients would be beneficial.
In this study, we aimed to assess the recurrence patterns in patients with oesophageal squamous cell carcinoma after trimodality treatments, and identify risk factors for disease recurrence, particularly distant recurrence.
PATIENTS AND METHODS

Study population
A prospectively maintained database of patients with oesophageal cancer was retrospectively reviewed. Between 2009 and 2015, there were 357 patients who had undergone an oesophagectomy for cancer at the Taipei Veterans General Hospital. The inclusion criterion for this study was patients who received preoperative chemoradiotherapy followed by surgery as the initial treatment modality. The exclusion criteria were patients with non-squamous cell carcinoma, and patients who received palliative resections. The Institutional Review Board of the TaipeiVeterans General Hospital approved this study and granted a waiver for the requirement of informed consent.
Staging workup
Pre-treatment staging workup included a systematic physical examination, standard laboratory screening, an oesophagogastroduodenoscopy, flexible bronchoscopy for tumours in the upper or middle third of the oesophagus, a computed tomography (CT) scan from the neck to upper abdomen, and a whole body fluorodeoxyglucose positron emission tomography/ computed tomography (FDG PET/CT). Endoscopic ultrasound (EUS) was a recommended procedure, particularly for the confirmation of cT1 or cT2 lesions; however, this was not routinely performed for every patient.
Preoperative chemoradiotherapy
Preoperative chemoradiotherapy included two courses of chemotherapy that were administered with a 4-week interval.
The chemotherapy regimen included 80 mg/m 2 of cisplatin administered intravenously on day 1, followed by continuous intravenous infusion of 600 mg/m 2 5-fluorouracil (5-FU) through days 1 to 4. This was administered concurrently with 45-50. 4 Gy of external-beam radiation, with the dose per fraction of 1.8 to 2 Gy for primary tumours and mediastinal lymph node regions. The clinical target volume was defined as the gross target tumour volume delineated on CT scans and other diagnostic images, along with 3-5 cm cephalic and at least 5 cm caudal margins. A chest CT scan was routinely performed after chemoradiotherapy to determine the resectability.
Surgical resection
Surgical resections included the McKeown tri-incisional oesophagectomy method used with either open thoracotomy, video-assisted thoracoscopic surgery (VATS), or robotic-assisted thoracoscopic surgery (RATS) approaches for oesophageal resection. Ivor-Lewis oesophagectomy (laparoscopy and right sided VATS) was performed in the event that tumours were close to the oesophagogastric junction. The details of the surgical procedures have previously been described [11] .
Pathological examination
Pathological examinations were conducted according to the seventh edition of the American Joint Committee on Cancer (AJCC) TNM staging system [12] . The tumour response was graded using the College of American Pathologist (CAP) Cancer Protocol for Esophageal Carcinoma [13] . Tumour regression grade (TRG) 0 (complete response) indicated no residual cancer cells. TRG 1 (moderate response) was defined as minimal residual cancer; TRG 2 (minimal response), as partial regression of the tumour; and TRG 3 (poor response) indicated that there was no definite response identified. The presence of LVI, PNI, and lymph node metastasis with extracapsular invasion (ECI), which was defined as the extension of the tumour through the nodal capsule and infiltrating into the perinodal adipose tissue stained with haematoxylin and eosin, were recorded. The presence of tumour cells at the vertical margin or within 1 mm of the circumferential resection margin upon microscopic evaluation was recorded as a positive surgical margin.
Follow-up protocol
The indications for adjuvant treatments after oesophagectomy included advanced tumour stage, presence of poor prognostic factors, and positive surgical margins. However, the decision for adjuvant treatments also depended on the patient s postoperative performance. All patients were followed-up in our outpatient department with an interval of 3 months for the first 2 years, 6 months for 2-5 years, and then annually. Routine follow-up assessments included physical examinations and CT scans from the neck to the upper abdomen. Endoscopies, radionuclide bone scans, and FDG PET/CT were obtained as clinically indicated. Diagnosis of recurrence was based on histological, cytological, or radiological evidences. When histological or cytological sampling was not possible, definitive radiological evidence was required. Disease recurrence was classified as loco-regional or distant. Locoregional recurrence was defined as recurrence at the anastomotic site, or within the area of the previous resection and nodal clearance in the cervical, mediastinum, or celiac regions. Distant recurrence included distant lymph node dissemination (such as to the para-aortic nodes), haematogenous metastasis to solid organs, or recurrence in the pleura or peritoneal cavities. OS was defined as the time from the date of diagnosis until death or last known follow-up. Recurrence-free survival was defined as the time from the date of surgical resection until the earliest date of recurrence, death, or last known follow-up. To decrease the impact of patient comorbidities and focus on the time at which residual cancer reached clinical significance sufficient to be recognized as recurrence, we calculated recurrence-free interval (freedom from recurrence), which was similar to the recurrence free survival, however only recurrences were counted as events.
Statistical analysis
Pearson's v 2 test was used to compare categorical variables. The student's t-test and ANOVA were used for the comparison of continuous variables. The Cox regression model was utilized for univariable and multivariable survival analysis. The backward method was used to optimize the multivariable model. Survival curves were plotted using the Kaplan-Meier method and compared by the log-rank test. All calculations were performed using Statistical Product and Service Solutions (version 17, SPSS Inc., Chicago, IL, USA) and a two-sided P-value < 0.05 was considered significant.
RESULTS
Patient characteristics
A total of 116 patients were eligible for this study (Fig. 1) . Table 1 shows the detailed clinical and pathological characteristics of included patients. The mean ± standard deviation (SD) and median age were 55.9 ± 9.3 and 58 (range: 36-84) years, respectively. Staging workup revealed the depth of tumour invasion to be (cT3/ 4 stage) in 79% (91/116) of patients and lymph node involvement (cN (+)) in 84% (97/116) of patients. After chemoradiotherapy, a pathologic complete response (ypT0N0) was seen in 36% (42/116) of patients. When comparing the clinical stages and the pathological stages, 66% (77/116) of patients had down staging in T status (cT stage > pT stage) and 50% (58/116) in N status (cN+&cenveo_unknown_entity_wingdings_F0E0;pN0). Minimally invasive oesophagectomy, either VATS or RATS, was performed in the majority of patients, whereas only 14% (16/116) of patients underwent an open thoracotomy for oesophageal resection. The mean ± SD and median number of total resected lymph node was 20.4 ± 14.6 and 17 (range: 2-99), respectively. Surgical margins were positive in 24% (28/116) of patients, including 7 (6%) with tumour cells in the vertical margin, 17 (15%) with tumour cells in the circumferential margin, and 7 (6%) with circumferential margins less than 1 mm.
Survival analysis
The mean follow-up time for the entire cohort was 24.7 months (range: 3-81) and 32.3 months (range: 4-81) for surviving patients. The median OS was 26.0 months [95% confidence interval (CI), 16.6-35.4 months), with estimated 1-, 3-, and 5-year OS rates of 78, 43 and 34%, respectively. The univariable analysis identified ypT stage, ypN stage, TRG, LVI, PNI, ECI, and the surgical resection margin as significant prognostic factors; however, only ypT stage [hazard ratio (HR): 1.322; 95% CI: 1.040-1.681; P = 0.02] remained significant in the multivariable analysis. The median recurrence-free survival rate after surgery was 10 months (95% CI: 7.2-12.8 months), with estimated 1-, 3-, and 5-year recurrence-free rates of 48, 29 and 22%, respectively. The univariable analysis identified ypT stage, ypN stage, TRG, LVI, PNI, ECI, and the surgical resection margin as significant prognostic factors, and ypT stage (HR: 1.501; 95% CI: 1.257-1.792; P < 0.001) and ECI (HR: 1.827; 95% CI: 1.043-3.200; P = 0.04) remained significant in the multivariable analysis. 
Recurrence patterns
Tumour recurrence arose in 53% (61/116) of patients, including 25 loco-regional recurrences and 49 distant recurrences (Table 2) . Thirteen patients had both loco-regional and distant recurrences. The median time to recurrence was 6 months after surgery. With respect to the loco-regional recurrences, more than half of patients (52%, 13/25) presented with mediastinal lymphadenopathy. The estimated 1-and 3-year freedom from loco-regional recurrence was 81 and 68%, respectively. In the univariable analysis (Table 3) , a positive surgical margin was the only significant prognostic factors for loco-regional recurrence (HR: 2.452; 95% CI: 1.034-5.815, P = 0.04). For distant recurrences, lung (20/49, 51%), liver (10/49, 20%) and bone (10/49, 20%) were the most common sites. The estimated 1-and 3-year freedom from distant recurrence rates were 56 and 50%, respectively. Unfavourable prognostic factors for distant recurrence in the univariable analysis included cN stage, ypT stage, ypN stage, TRG, LVI, PNI, ECI and positive surgical margin (Table 4 ). In the multivariable analysis, the independent factors significantly associated with distant recurrence were cN stage (HR: 4.049; 95% CI: 1.242-13.200, P = 0.02), LVI (HR: 3.658; 95% CI: 1.891-7.078, P < 0.001) and ECI (HR: 2.393; 95% CI: 1.202-4.763, P = 0.01). Male  109  94  Female  7  6  Clinical stage  T1N+  3  3  T2N0  6  5  T2N+  16  14  T3N0  12  10  T3N+  73  63  T4N0  1 
Lymphovascular invasion and extracapsular invasion as predictors for distant recurrence
When predicting distant recurrence based on histological examinations, the 1-and 3-year freedom from distant recurrence rates were 72 and 66% when both LVI and ECI factors were absent, compared to 18 and 14% when either or both were present (P < 0.001, Fig. 2 ). The 1-and 3-year distant recurrence free survival rates were 58 and 42% when both factors were absent, compared to 16 and 6%, respectively, when either or both were present (P < 0.001, Fig. 3 ). When investigating whether the correlation between LVI, ECI and tumour stage, we found that LVI was closely correlated with ypT stage. Eleven percent (4/35) of patients with ypT1/2 stage had positive LVI, compared to 41% (16/39) of patients with ypT3/4 stage (P < 0.001). Moreover, ECI was closely correlated with lymph node metastasis. 30% (6/20) of patients with lymph node ratio < _ 0.1 had positive ECI, compared to 65% (13/20) of patients with lymph node ratio > 0.1 (P = 0.03).
DISCUSSION
We previously reported patterns of recurrence in 268 patients undergoing upfront surgery without preoperative chemoradiotherapy. Locoregional, distant and combined recurrences occurred in 36, 44 and 21% patients, respectively [14] . In the current study, the patterns of recurrence in patients after preoperative chemoradiotherapy and oesophagectomy included loco-regional recurrence in 29%, distant recurrence in 59%, and combined recurrence in 21% of patients. Our single centre study was consistent with previous observations that preoperative chemoradiotherapy reduces the loco-regional recurrence rate, and that the majority of patients had recurrence at distant sites after trimodality treatments [3, 8, 10] . The detailed histopathological specific for loco-regional or distant recurrences after trimodality treatments for oesophageal cancer are poorly defined in the literature. Our findings regarding the significance of surgical resection margin, LVI and ECI, were consistent with previous reports [15] [16] [17] [18] [19] [20] [21] [22] [23] . In a large multicentre European study of 2815 patients, Sheraz et al. showed that R1 resection margin was significantly associated with reduced survival and increased tumour recurrence rates [15] . Subgroup analysis in patients after preoperative chemoradiotherapy showed that the R1 resection margin was an independent predictor of poor prognosis (HR 1.51, P = 0.021) by multivariable analysis, and was associated with an increase in the number of cases of loco-regional recurrence (HR 2.17, P < 0.001). Using the criteria established by the Royal College of Pathologists [16] , which requires at least 1 mm of uninvolved tissue around the tumour for the radial margin to be deemed negative, Chao et al. [17] reported that patients with positive radial margins after preoperative chemoradiotherapy had significantly higher probability of loco-regional recurrence than those with negative margins.
LVI, which is characterized by the ability of tumour cells to penetrate into the peritumoural vascular or lymphatic network, is considered as an important step for tumour spreading. It has been reported that LVI is significantly correlated with lymphangiogenesis, which is the primary route for tumour dissemination and the emergence of systemic disease [18] . Lagarde et al. [9] demonstrated that venous invasion, lymphatic invasion and PNI, or a combination of these events, were independent prognostic factors for disease free survival in patients after preoperative chemo-or chemoradiotherapy and oesophagectomy. However, less than a quarter of patients in their study had squamous cell carcinoma, which, when compared to adenocarcinoma, was associated with a lower frequency of venous invasion (33 vs 39%) and lymph vessel invasion (37 vs 55%). In patients with oesophageal squamous cell carcinoma who were treated with preoperative chemoradiotherapy and oesophagectomy, Chen et al. reported that LVI was noted in 37% of patients with persistent tumours in the resected specimens. They reported that the presence of LVI was associated with advanced T stage, lymph node metastasis, and worse OS [19] . In the current study, LVI was noted in 23% of patients and was a significant risk factor specific to distant recurrence.
Lymph node dissemination is one of the most important prognostic factors in oesophageal cancer [20, 21] . ECI, which is the phenomenon by which cancer cells extend through the nodal capsule into the perinodal fatty tissue, has been regarded as the invasiveness and aggressiveness of the primary tumour [21] . In a systematic review on meta-analysis, Luchini et al. [22] reported that the presence of ECI of lymph node metastasis was associated with a significantly increased risk of all-cause mortality, cancerspecific mortality and risk of recurrence in oesophageal cancer. In D'Journo's study, 14% of patients had ECI in the resected oesophageal specimens after preoperative chemoradiotherapy. The 5-year disease-free survival rates were 46% in N0 patients, 36% in N+ with intracapsular invasion patients, and 11%, in N+ with ECI patients [23] . Knowing the importance of ECI in esophageal cancer has impact on both surgical resection and pathological examination Since ECI can be focal in a metastatic lymph node, complete surgical removal of all the lymph nodes in addition to the surrounding fatty tissue, as opposed to simply isolating it from the fatty tissue is recommended. For surgical pathologists, it is necessary to examine the lymph nodes and all the perinodal adipose tissue, as opposed to examining the lymph nodes in isolation from the surrounding tissue, and determining the presence of metastasis based on the status of the lymph nodes alone. In the current study, ECI was noted in 16% of patients, and the presence of ECI was a significant prognostic factor for both recurrence free survival and freedom from distant recurrence.
Disease failures after trimodality treatments may be a result of unidentified persistent local disease, undetected micrometastasis, failures of systemic treatments, or a combination of the above reasons [10] . The patterns of disease recurrence may reflect the effectiveness of combined treatments, as well as the subsequent treatment planning. As surgical resection margins are the predominant predictors of loco-regional recurrence, it seems logical to advocate radical surgery and extended lymphadenectomy, or intensifying the radio sensitising effect of chemotherapy by widening irradiation fields and increasing radiotherapy doses to improve loco-regional tumour control [4, 10] . With regard to distant recurrence, the importance of LVI and ECI indicated that tumour biology, with its intrinsic sensitivities to chemoradiotherapy, may be the most critical determining factor. Another risk factor for distant recurrence was N stage at pretreatment, which indicated systemic dissemination before the administration of treatment. All these findings indicated that the systemic efficacy of current chemoradiotherapy is inadequate. In addition to the intensive surveillance of patients with these high risk factors, efforts must be made to improve systemic tumour control by the use of more aggressive chemotherapy regimens, or by establishing sensitivity tests facilitate the targeting of tumours with agents to which they are sensitive [4, 7] . Randomized trials are needed to elucidate this issue further. For example, the Preoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer (PROTECT) trial aims to evaluate the short-term benefit and safety of two preoperative regimens, (carboplatin-paclitaxel or fluorouracil-oxaliplatin-folinic acid), combined with the radiation regimen used in the CROSS study [1, 24] . The results of this trial are currently being awaited. With respect to the radiation doses, no randomized study indicating any benefit or detriment associated with the use of dose ranges over 50-50.4 Gy could be found in the literature. In a recent report, the dose analysis, binned as 50-50.4, 51-54, 55-60 and >60 Gy, revealed no appreciable difference in survival within any group compared with a 50-50.4 Gy dose [25] .
Limitations
One of the strengths of our current study is that it involves the use of detailed histological factors to predict recurrence, and both pretreatment staging and post-treatment follow-up were discussed at the multidisciplinary tumour board conference. However, the limitations of this study include the relatively small number of patients analysed, and the fact that histological examinations were based on haematoxylin and eosin staining without the use of immunohistochemical markers. Furthermore, this study assessed patients with squamous cell carcinoma only; therefore, our results need further validation in larger samples that includes patients with both adenocarcinoma and squamous cell carcinoma.
CONCLUSIONS
Whilst a positive surgical resection margin was the significant factor for loco-regional recurrence, the presence of LVI and ECI identified patients at high risk of distant recurrence after preoperative chemoradiotherapy and oesophagectomy. Effective systemic therapy and intensive surveillance are necessary in this group of patients.
